StockNews.AI
PCRX
StockNews.AI
175 days

Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline

1. PCRX faces a class action lawsuit for alleged securities fraud. Investors are impacted. 2. Court invalidated PCRX's key '495 patent for Exparel. Revenue vulnerability increases. 3. Stock price dropped over 47% in one day post-announcement. Investor losses were severe. 4. Class action lawsuit offers no-cost recovery for affected shareholders. Participation is time-sensitive.

4m saved
Insight
Article

FAQ

Why Very Bearish?

PCRX’s dramatic price drop following the invalidation of its core patent mirrors historical biotech turmoil when litigation erodes investor confidence.

How important is it?

The lawsuit directly challenges PCRX’s main revenue source and compounds litigation risks, marking a significant near-term concern.

Why Short Term?

Immediate legal challenges and investor sentiment shifts are likely to drive near-term volatility, as seen in past similar cases.

Related Companies

PCRXeVenus
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=131745&wire=4 PCRX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on August 9, 2024, Pacira issued a press release announcing the results of its lawsuit against eVenus for patent infringement. Pacira disclosed that the court "found that the company's U.S. Patent No. 11,033,495 (the '495 patent) is not valid," and, thus, eVenus is not infringing on anything. Pacira's '495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the '495 patent calls into question the validity of the Company's other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward.  Following this news, Pacira's common stock declined dramatically. From a closing market price of $22.36 per share on August 8, 2024, Pacira's stock price fell to a low of $11.70 per share on August 9, 2024, a decline of over 47% in a single day. WHAT'S NEXT? If you suffered a loss in Pacira during the relevant time frame, you have until March 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News